Gilead Sciences Inc
Gilead Sciences Inc (GILD) Historical Volatility
GILD's 30 day historical volatility is 31.49%, in the 81st percentile of readings over the past year. This is a high percentile, meaning Gilead Sciences Inc shares have swung far more than usual. GILD's 30 day implied volatility sits at 32.03%, with an IV Rank of 65.08%, leaving IV roughly in line with historical volatility. This means options are priced close to what the stock has actually delivered, as of Nov 16, 2026.
Read more
Tracking GILD historical volatility helps you see how much Gilead Sciences Inc's stock price has actually moved, giving you a baseline for whether option premiums look fair, cheap, or expensive. While implied volatility shows what the market expects, GILD's HV, also known as realized volatility, shows what actually happened. Use our scanner to monitor GILD 30 day historical volatility alongside longer lookback windows and spot the moments when realized and implied diverge.
Historical volatility is the annualized standard deviation of a stock's past returns, typically measured over rolling windows like 10, 20, 30, or 60 days. GILD's 30 day historical volatility, or GILD HV, is one of the most widely watched readings because it balances responsiveness with stability. Comparing GILD's HV to its implied volatility reveals the volatility risk premium. When IV sits well above HV, options are pricing in more movement than the stock has actually delivered, giving option sellers an edge. When HV runs hot relative to IV, options are pricing in less movement than the stock has delivered, and buyers may be underpaying for it.
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases. It also offers Yescarta, Tecartus, Trodelvy, and Zydelig products for the treatment of hematology, oncology, and cell therapy patients.
Historical Volatility
Historical movement is elevated versus the past year. The stock has been unusually active.
As of Nov 16, 2026
As of Nov 16, 2026
As of Nov 16, 2026
Prices move. This one stays.Lock in 5 years at a special price and save $1,503. Ending soon.See the Black Friday deal →